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agents to deliver drugs, nanoparticles and imaging agents. Although in nature, several protein-
mediated signal transduction events depend on RGD motifs, the potential of RGD-empowered 
materials in triggering undesired cell signalling cascades has been neglected. Using an RGD-
functionalized protein nanoparticle we show here that the RGD motif acts as a powerful trophic factor, 
supporting extracellular signal-regulated kinase 1/2 (ERK1/2)-linked cell proliferation and partial 
differentiation of PC12 cells, a neuron-like model. 
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Reviewer #1: It is of interest that HNRK was found to stimulate PC12 cell growth at 
levels comparable or even higher than those promoted by the nerve growth factor 
(NGF).  The study provides a novel and potentially powerful idea for nanomedicine and 
namely that the vehicle itself could provide trophic factor support through supporting 
ERK-linked cell proliferation and partial differentiation.  The question remains is what is 
observed in a cell line reflective of what may occur with primary cells.  Stimulation of 
cell proliferation in tumor cells can occur through a broad range of factors that include 
growth factors, cell signaling events, cytokines, chemokines and others.  If a case is 
made for these findings to affect neuronal cells than the findings need to reproduced in 
primary neurons.  This is ever important as NGF is well known to promote neuronal 
differentiation of PC12 pheochromocytoma cells. This has been reported to occur 
within 5 min after NGF addition. Thus, stating that as yet undisclosed factor engaging 
these cells is more powerful in its effects than NGF requires cross validation of the data 
set. 
We agree with the referee in that cross validation of data would make our 
message stronger. We also believe that testing RDG with primary neuronal 
cultures would probably not the best experimental model as they are highly 
differentiated cells. We have chosen to offer data showing RDG-promoted ERK 
activation in primary glial cell cultures (panel C in the new Figure 4). Being 
suitable for the requested cross validation, these positive results also indicate 
that the reported trophic effects are not restricted to a specific lineage, in the 
context of the point 2 raised by the referee #2.  
 
 
Reviewer #2: The paper is interesting and well written.  I have only a few comments. 
We appreciate the positive opinion of the referee. 
 
*Detailed Response to Reviewers
1.      Although very well researched, I don't know that it's fair to say that RGD peptides 
are 'the most universal tags for targeted delivery of drugs and nanoparticles'. 
We fully agree with the referee. The sentence in the graphical abstract has been 
modified as follows: … that RGD peptides, among the most used tags for 
targeted delivery of drugs and nanoparticles…..   
 
2.      I think that other cell types, especially endothelial cells, need to be explored 
before the RGD cell trophic properties could be defined as of 'strategic interest' in the 
design of targeted therapeutics. 
We agree. We have toned down this sentence as follows: ….potential interest…. 
However, we have shown that the trophic effect of RGD is not restricted to 
neuronal lineage, as shown in Figure 4 C by incorporating studies with primary 
glial cell cultures. 
 
3.      Page 3, 2nd paragraph after (Figure 1 c) change 'what' to that and add a 
semicolon after the parentheses. 
Done 
 
 
 
Reviewer #3: Specific comments: 
1.      Page 2, line 3: motive is wrongly given instead of motif. Done. 
2.      Page 3, line 12: motive is wrongly given instead of motif. Done. 
3.      Page 3: The source of the PC12 cell is not mentioned. Done in the 
Supplementary Information. We have also indicated the source of the other cell 
lines employed in the study. 
4.      Fig 2.C: In Y axis MTT % must be changed into Viability %. Done, and also in 
Figure 4. 
5.      Reference 5: Volume and page number must be included. Done. 
6.      Reference 9: Page number must be included. The book reference has been 
completed according to the journal style. 
7.      More relevant and clear title can be given for Graphical abstract below the image. 
Changed into: RGD peptides are potent trophic factors. 
General comments: 
1.      Most of the abbreviations like ERK (abstract, line No: 6), HNRK, etc.  are not 
explained properly. ERK was defined in page 2, end of the first paragraph, but we 
have now defined it again in the abstract to make it clearer. HNRK is not an 
abbreviation but the name given to the modular protein. We now explicitly 
indicate the meaning of all the consecutive protein segments. In addition, we 
have carefully revised the MS to ensure that all the abbreviations are clearly 
explained. 
2.      Figures 3.A, clarity can be improved. We are not sure if we correctly 
understand the referee’s point. Figure 3A is an in situ immunodetection of MAP-2 
in cells growing under 20 % serum and it represents a control for the experiment 
shown in the figure.  The field selected for panel A matches that shown in panel 
B. In its present form, the figure is reasonably clear and it cannot (and should 
not) be manipulated without losing its value as a control.  
  
 
RGD peptides are potent trophic factors. 
We describe here that RGD peptides, among the most used tags for targeted 
delivery of drugs and nanoparticles promote protoneurite formation, p-ERK1/2-
dependent cell division in absence of serum and expression of neuronal 
markers (MAP-2) in model PC12 cells. The trophic potential of RGD peptides is 
an unexpected event of critical relevance in the functionalization of drugs and 
their nanocarriers.  
Graphical Abstract: Text
Graphical Abstract: Image
Click here to download Graphical Abstract: Image: Graphical abstract.ppt
 1 
 
RGD-based cell ligands for cell-targeted drug delivery 
act as potent trophic factors  
 
 
 
Joan Domingo-Espín 1, 2, 3, Valérie Petegnief 4, Núria de Vera 4, Oscar Conchillo-Solé 1, 
Paolo Saccardo1, 2, 3, Ugutz Unzueta 1, 2, 3, Esther Vazquez 1, 2, 3, Juan Cedano 5, Luciana 
Negro 6, Xavier Daura 1,6, Hugo Peluffo 7,8, Anna M. Planas 4, Antonio Villaverde 1, 2, 3 *, 
Neus Ferrer-Miralles 1, 2, 3 
 
1 Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, 
Bellaterra, 08193 Barcelona, Spain 
2 Department of Genetics and Microbiology, Universitat Autònoma de Barcelona, 
Bellaterra, 08193 Barcelona, Spain 
3 CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Bellaterra, 
08193 Barcelona, Spain 
4 Departament d’Isquèmia Cerebral i Neurodegeneració, Institut d’Investigacions 
Biomèdiques de Barcelona (IIBB), Consejo Superior de Investigaciones Científicas 
(CSIC)-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, 
Spain 
5 Laboratory of Immunology, Regional Norte, Universidad de la Republica, Gral. Rivera 
1350; Salto, 50.000, Uruguay 
6 Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain 
7 Neurodegeneration Laboratory, Institut Pasteur de Montevideo, CP 11400, 
Montevideo, Uruguay 4 
8 Department of Histology & Embryology, Faculty of Medicine, UDELAR, CP 11800, 
Montevideo, Uruguay 
 
* Corresponding author: A. Villaverde; Institut de Biotecnologia i de Biomedicina, 
Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain. Phone:+34 
935813086; Fax: +34 935812011. E-mail:  antoni.villaverde@uab.cat 
 
 
Keywords: Protein nanoparticles; integrins; RGD; neurons; nanomedicine; 
biomaterials 
  
Number of words in the text body, including abstract and figure legends:  1444 
Number of Figures: 4 
Number of Tables: 0 
Number of references: 10 
*Revised Manuscript
 2 
ABSTRACT 
Integrin-binding, arg-gly-asp (RGD)-containing peptides are the most widespread used 
agents to deliver drugs, nanoparticles and imaging agents. Although in nature, several 
protein-mediated signal transduction events depend on RGD motifs, the potential of 
RGD-empowered materials in triggering undesired cell signalling cascades has been 
neglected. Using an RGD-functionalized protein nanoparticle we show here that the 
RGD motif acts as a powerful trophic factor, supporting extracellular signal-regulated 
kinase 1/2 (ERK1/2)-linked cell proliferation and partial differentiation of PC12 cells, a 
neuron-like model. 
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Innovative medicines aim to the cell-targeted delivery of therapeutic cargos. The 
concept supporting this approach is that specific binding to selected cell surface 
receptors should result in improved biodistribution and enhanced cellular penetrability. 
Since the discovery of the arg-gly-asp (RGD) motif as a potent ligand of cell surface 
integrins (mainly σvß3) (1), RGD-containing peptides have been massively used to 
control drug biodistribution, being the most employed agents for cell targeting and 
endosomal delivery (2). As integrins abound in endothelial cells and because of the 
high vascularisation of tumoral tissues, RGD-mediated drug-delivery is of special 
interest in cancer therapies (2). Interestingly, some RGD-containing natural proteins, 
including fibulin-5 (3), osteopontine (4), the angiogenic factor Del1 (5) and the dentin 
matrix acidic phosphoprotein 1 (DMP1) (6), act as biological effectors through their 
RGD motifs, at least some of them through the extracellular signal-regulated kinase 1/2 
(ERK1/2)-mitogen-activated protein kinase (MAPK) pathway. Therefore, it would not be 
unexpected that RGD-empowered constructs for drug targeting could trigger side 
responses in target cells, although this possibility has not been investigated.  
 
HNRK is a short modular protein of 91 amino acids in length, consisting of 4 
consecutive functional peptides, namely an endosomolytic poly-histidine peptide (H), a 
viral nuclear localization signal (N), an RGD-containing site of foot-and-mouth disease 
virus (FMDV) serotype C1 (R) and a C-terminal poly-lysine (K) peptide (Figure 1 a). In 
the presence of plasmid DNA, HNRK forms 80 nm-polyplexes efficient in DNA delivery 
to mammalian cells (7). The transfection efficiency of HNRK nanoparticles is highly 
dependent on the amount of αvβ3 displayed on the cell surface (Figure 1 b), indicating 
that the RGD stretch determines the capability of the construct to penetrate the target 
cell and deliver the cargo. Contrarily, HKRN, a modular isoform of HNRK (Figure 1 a) 
fails to promote high levels of transgene expression (Figure 1 c), a fact that could be 
attributed to a poor presentation of the cell ligand. In this regard, in a homology model 
of HNRK, RGD is folded as a mirror-like structure of the parental viral segment, while in 
HKRN the segment folds in part as a mirror and in part as a fully matching 
conformation, stabilized by different interactions (Figure 1 d). Interestingly, when 
exposing PC12 cells to HNRK alone (but not to HKRN), proto-neurite formation was 
unexpectedly observed (Figure 2 a, and Supplementary figure). In this context, HNRK 
specifically stimulated PC12 cell growth at levels comparable or even higher than those 
promoted by the nerve growth factor (NGF) (Figure 2 b, c). Both the morphological 
modification of PC12 cells and the enhanced cell growth upon exposure to HNRK 
indicated that this protein could act as a cell trophic factor. Since HKRN, in which the 
displayed RGD is unable to efficiently bind integrins did not stimulate cell survival, 
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growth and differentiation, it could be speculated that a functional RGD motif could be 
responsible for the HNRK-induced trophic effect. This was fully supported by the fact 
that the HNRK variant HN(RGE)K, in which the RGD sequence was mutated into the 
non-binding RGE motif, did not show trophic effects (Figure 2 b, c). 
 
To explore the biological effects mediated by HNRK, we analyzed the signaling events 
in HNRK-exposed PC12 cells through the expression of microtubule associated 
proteins typically used as neuronal markers. Indeed, HNRK up-regulated microtubule-
associated protein-2 (MAP2) (Figure 3) and Tau (not shown). Interestingly, HNRK but 
not HN(RGE)K also stimulated the phosphorylation of ERK1/2 (Figure 4 a). The degree 
of ERK1/2 phosphorylation induced by HNRK was lower than that triggered by NGF, 
while in contrast, the chimeric protein stimulated cell proliferation more than NGF did 
(Figure 2). These results suggest different effector pathways for NGF and HNRK. 
PD98059, an inhibitor of the MAPK kinases MEK1 and 2 that phosphorylates ERK1/2, 
reduced NGF-induced ERK1/2 phosphorylation and fully abolished HNRK-induced 
ERK1/2 phosphorylation (Figure 4 a). Interestingly, while cell proliferation mediated by 
HNRK was significantly reduced by more than 50 % by PD98059, this inhibitor only 
showed a trend for reduction of NGF-induced cell proliferation by around 15 % (Figure 
4 b). 
 
Finally, to explore whether the trophic effects of RGD described here could be 
restricted to a specific cell lineage (neurons) we extended our study to rat primary glial 
cell cultures enriched in astrocytes. In this additional model, a dose-dependent ERK1/2 
phosphorylation was clearly observed upon exposure to HNRK, indicating that the 
effector role of the peptide motif is instead a generic event (Figure 4c). 
 
The tripeptide RGD is one of the most used cell ligands in Nanomedicine for the 
targeted delivery of drugs, as associated with chemicals, protein-only constructs, self-
assembling peptides, liposomes, dendrimers, carbon nanotubes, magnetic 
nanoparticles, quantum dots, polymers and other delivery agents (8;9). RGD is also 
used as a cell binding agent in cell culture and in different approaches of tissue 
engineering as a functional coating agent to favor cell binding to the substrate and 
differentiation (10). Therefore, the cell trophic activities of RGD described in the 
present study are of potential interest when evaluating the biological and therapeutic 
effects of RGD-based therapies, as the side effects of the vehicle might antagonize or 
synergistically act with those of the therapeutic cargo. This might be of special interest 
if the nanoparticle-linked drug is intended to arrest cell growth or is a cell killing agent, 
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as it usually occurs in antitumoral therapy. Importantly, the catalogues of agents used 
in nanomedicine for cell targeting are rich in natural or mimetic ligands of receptors for 
hormones, cytokines or other effectors that might potentially trigger signaling events.  
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Legends for the figures 
 
Figure 1: A. Schematic representation of HNRK and HKRN (modified from (7)). B. 
Relationship between the percentage of integrin positive cells and transgene 
expression levels mediated by HNRK. C. Percentage of HeLa and GL261 transfected 
cells, mediated by HNRK-DNA or HKRN-DNA nanoparticles. D. Detail of the residues 
closer than 4 A to the arg residue in the RGD module (in white, in yellow, the rest of the 
peptide), modeled using the segment 134-156 from FMDV VP1 (pdb 1QGC). In the 
insets, superposition of the recombinant RGD modules (blue) over the template (red) 
used to model it, again residues 134-156 from FMDV VP1 (pdb 1QGC). Details of all 
the experimental procedures used in the study can be found in the Supplementary 
information. 
 
Figure 2: A. Magnifications of HNRK- and NGF-treated cells (at 100 ng/ml). Scale bar= 
20 m. Proliferation of PC12 cells monitored by cell counting (B) or relative MTT 
activity (C). Cells were cultured for 7 days in the absence of serum (Cell –S); with 20 % 
serum (Cell +S); in absence of serum plus NGF; in absence of serum plus either HNRK 
or HN(RGE)K. Only significantly different pair of comparative data are indicated 
(p<0.01, n=3). 
 
Figure 3: Immunofluorescence for MAP-2 (red) in cells either maintained under control 
conditions (20 % serum) (A, B), or treated with NGF (C, D) or HNRK (E, F). Nuclei are 
stained with DAPI (blue) in B, D, F. Neurite extensions are indicated by arrows. Scale 
bar= 50 m. 
 
Figure 4. A. ERK1/2 phosphorylation determined by Western blotting (n=3). -Tubulin 
is shown as a gel loading control. B. Cell viability determined by MTT assay. Only 
significantly different pair of comparative data are indicated (p<0.01, n=3). C. ERK1/2 
phosphorylation determined by Western blotting two hours after exposure of astrocyte-
enriched glial cell cultures to HNRK (75 ng/l and 150 ng/l respectively). -Tubulin is 
also shown as a gel loading control. C indicates non-exposed control cells. 
 7 
 
Reference List 
 
 1.  Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and 
integrins. Science 1987;238:491-7. 
 2.  Meyer A, Auernheimer J, Modlinger A, Kessler H. Targeting RGD recognizing 
integrins: drug development, biomaterial research, tumor imaging and targeting. 
Curr.Pharm.Des 2006;12:2723-47. 
 3.  Yue W, Sun Q, Landreneau R, Wu C, Siegfried JM, Yu J et al. Fibulin-5 
suppresses lung cancer invasion by inhibiting matrix metalloproteinase-7 
expression. Cancer Res. 2009;69:6339-46. 
 4.  Tanabe N, Wheal BD, Kwon J, Chen HH, Shugg RP, Sims SM et al. Osteopontin 
signals through calcium and nuclear factor of activated T cells (NFAT) in 
osteoclasts: a novel RGD-dependent pathway promoting cell survival. 
J.Biol.Chem. 2011;286:39871-81. 
 5.  Wang Z, Kundu RK, Longaker MT, Quertermous T, Yang GP. The angiogenic 
factor Del1 prevents apoptosis of endothelial cells through integrin binding. 
Surgery 2011; 151:296-305. 
 6.  Eapen A, Ramachandran A, Pratap J, George A. Activation of the ERK1/2 
mitogen-activated protein kinase cascade by dentin matrix protein 1 promotes 
osteoblast differentiation. Cells Tissues.Organs 2011;194:255-60. 
 7.  Domingo-Espin J, Vazquez E, Ganz J, Conchillo O, Garcia-Fruitos E, Cedano J 
et al. Nanoparticulate architecture of protein-based artificial viruses is supported 
by protein-DNA interactions. Nanomedicine (Lond) 2011;6:1047-61. 
 8 
 8.  Dunehoo AL, Anderson M, Majumdar S, Kobayashi N, Berkland C, Siahaan TJ. 
Cell adhesion molecules for targeted drug delivery. J.Pharm.Sci. 2006;95:1856-
72. 
 9.  Villaverde A. editor. Nanoparticles in translational science and medicine, vol. 114, 
1st ed. London: Academic Press (Elsevier), 2011. 
 10.  Williams DF. The role of short synthetic adhesion peptides in regenerative 
medicine; the debate. Biomaterials 2011;32:4195-7. 
 
 
N                                                                       C H6 NLS RGD K10
HNRK 
N                                                                       C H6 K10 RGD NLS
HKRN 
0 
5 
10 
15 
20 
25 
0 10 20 30 40 50 60 
A 
B 
GL26 
HeLa 
Cos-1 
PC12 
Integrin content (%) 
T
ra
n
s
fe
c
te
d
 c
e
lls
 (
%
) 
HeLa GL261
0
5
10
15
20
25
HNRK 
HKRN 
T
ra
n
s
fe
c
te
d
 c
e
lls
 (
%
) 
C 
HNRK 
HKRN 
D 
Figure 1
A 
C 
B 
C
e
lls
/w
e
ll 
0 
50000 
100000 
150000 
200000 
250000 
300000 
350000 
Cell - S Cell + S NGF HNRK HN(RGE)K 
0 
50 
100 
150 
200 
250 
300 
350 
400 
Cell - S Cell + S NGF HNRK HN(RGE)K 
V
ia
b
ili
ty
 (
%
) 
p=0.00002 p=0.00001 
p=0.0012 p=0.0018 
p=0.0019 
Figure 2
Figure 3
PC12
HNRK 
PD98059PC12*NGF HNRK HN(RGE)K
NGF  
PD98059
HN(RGE)K
PD98059 DMSO
A 
V
ia
b
il
it
y
 (
%
) 
p=0.0069 
B 
 C          HNRK C 
Figure 4
  
Supplementary Material
Click here to download Supplementary Material: Supplementary information REVISED VERSION FINAL.doc
